Clinical Frailty Scale in prediction of mortality, disability and quality of life for patients in need of intensive care
Clinical Frailty Scale (CFS) is an assessment tool used to describe the frailty of a patient. The scale originated in Canada and was initially developed to estimate the need for institutional care and to predict life expectancy. The CFS version currently used has 9 levels (CFS-9) where an assessment of frailty is made between 1, very fit, to 9, terminally ill.
Question
Is the Clinical Frailty Scale able to predict mortality, disability or quality of life in patients admitted to intensive care, either due to respiratory tract infection or due to other cause?
Summary
SBU Enquiry Service identified 23 primary studies considered within the scope of the review question after literature search and study selection. Eleven studies were critically appraised as low to moderate risk of bias regarding at least one outcome. In the included studies, the Clinical Frailty Scale (CFS) was used to estimate the frailty of individuals prior to admission to intensive care. The included studies were mainly conducted on elderly patients in need of intensive care, where the cause of need for intensive care varied. None of the studies examined patients who exclusively had respiratory tract infections. The studies were published from 2014 and onwards, and most studies during the last two years. Most studies originated from Europe and Canada. Several were multicentre studies, in which some had participation from Swedish clinics. The studies that were appraised as having a low to moderate risk of bias are briefly described in the text below, and all studies are presented in Table 1 and in Appendix 3 and 4.
SBU Enquiry Service identified:
- Eight studies examined the validity and reliability of CFS in patients in intensive care (low to moderate risk of bias) [1–8]. Seven of these studies examined the prediction of mortality [1–5,7,8].
- Two studies evaluated to which degree CFS could predict future disability for patients in intensive care (moderate risk of bias) [4,6].
- One study examined to which degree CFS could predict future quality of life for patients in intensive care (moderate risk of bias) [4].
- Four studies examined interrater reliability for CFS in patients in intensive care (low to moderate risk of bias) [2,3,9,10].
In studies with low to moderate risk of bias, the results showed that frailty assessment with CFS to some extent could predict in-hospital mortality and 30-day mortality. The mortality increased with each unit of the frailty scale. DeGeer et al. 2020, found that frailty assessment with CFS could predict 30-day mortality with an AUC (area under curve) of 0.74 (95% CI, 0.9 to 0.79) [1]. Two studies analysed the optimal threshold value for predicting mortality, with the aim of being able to use the scale dichotomously and found that mortality substantially increased from scale-point CFS 5 and above [1,5].
In the study by Hope et al. 2019, the risk of disability at six months was associated with an increase per unit on the CFS scale [6]. In the study by Brummel et al. 2017, the risk of disability varied depending on the assessment tool used to assess disability level, as well as on the time of assessment. Regarding prediction of quality of life, the results presented by Brummel et al showed varying results [4].
It should be noted that no study showed that CFS was able to predict either outcome (mortality, disability or quality of life) of all individuals. This implies that, there will be patients who are assessed as having a high level of frailty but do not die within 30 days, as well as patients who are assessed as having a low level of frailty but that nevertheless die.
Table 1. Identified studies according to age and outcome (reference, risk of bias)
a Measures disability or death at 6 months as a combined endpoint. b Also presents 1-year mortality. c Also presents 6 months mortality. d These articles are based on the same patient material. |
|||||||
Outcome | |||||||
Age | ICU mortality In-hospital mortality |
30-day mortality | 90-day mortality | Disability | Quality of life | Test-retest reliability | |
≥18 years 7 studies |
Shears et al 2018, [3] Moderate Fernando et al 2019, [11] High Montgomery et al 2019, [12] High |
De Geer et al 2020, [1] Low |
Brummel et al 2017, [4] Moderate |
Brummel et al 2017, [4] Moderate Hope et ala 2017, [13] High |
Brummel et al 2017, [4] Moderate |
Shears et al 2018, [3] Moderate |
|
≥50 years 6 studies |
Bagshaw et alb 2014, [8] Moderate (for this outcome) Darval l et alc 2019, [14] High Kara et al 2018 [15] High Tipping et al 2019, [16] High |
Hope et ald 2019, [6] Moderate |
Bagshaw et al 2014, [8] High (for this outcome) |
Hope et ald 2019, [9] Moderate |
|||
≥60 years 1 study |
Pugh et al 2019, [10] High (for this outcome) |
Pugh et al 2019, [10] Moderate (for this outcome) |
|||||
≥65 years 3 studies |
Langlais et al 2018, [7] Moderate Fernando et al 2019, [17] High Le Maguet et alc 2014, [18] High |
||||||
≥70 years 1 study |
Silva-Obregon et al 2020, [19] High |
Silva-Obregon et al 2020, [19] High |
Silva-Obregon et al 2020, [19] High |
||||
≥80 years 3 studies |
Guidet et al 2020, [2] Low Flaatten et al 2017, [5] Low Darvall et al 2019, [20] High |
Guidet et al 2020, [2] Low Flaatten et al 2017, [5] Low |
Guidet et al 2020, [2] Low |
||||
Age not reported 2 studies |
Fisher et al 2018, [21] High |
Pugh et al 2017, [22] High |
Appendices
Appendix 1 Critical appraisal checklist.pdf
Appendix 2 Excluded studies.pdf
Literature search
Search terms | Items found | |
The search result, usually found at the end of the documentation, forms the list of abstracts.; [MeSH] = Term from the Medline controlled vocabulary, including terms found below this term in the MeSH hierarchy; [MeSH:NoExp] = Does not include terms found below this term in the MeSH hierarchy; [MAJR] = MeSH Major Topic; [TIAB] = Title or abstract; [TI] = Title; Systematic[SB] = Filter for retrieving systematic reviews; * = Truncation | ||
Population: | ||
1. | “Critical Care”[Mesh] | 56 746 |
2. | “Intensive Care Units”[Mesh] | 82 287 |
3. | “Critical Illness”[Mesh] | 27 989 |
4. | critical care[Title/Abstract] | 29 925 |
5. | Critical illness[Title/Abstract] | 8 819 |
6. | critically ill[Title/Abstract] | 43 135 |
7. | Intensive care[Title/Abstract] | 140 634 |
8, | ICU[Title/Abstract] | 54 277 |
9. | 1-8 (OR) | 248 489 |
10 | “Airway Management”[Mesh] | 133 633 |
11. | “Respiratory Insufficiency”[Mesh] | 63 557 |
12. | Influenza, Human[Mesh] | 48 335 |
13. | Pneumonia[Mesh] | 90 785 |
14. | Ventilat*[Title/Abstract] | 162 458 |
15. | Respirat*[Title/Abstract] | 485 671 |
16. | Airway*[Title/Abstract] | 159 850 |
17. | Intubat*[Title/Abstract] | 55 233 |
18. | Influenza[Title/Abstract] | 94 940 |
19. | Pneumoni*[Title/Abstract] | 177 432 |
20. | Pulmonary[Title/Abstract] | 535 174 |
21 | Lung*[Title/Abstract] | 633 130 |
22. | 10-21 (OR) | 1 782 341 |
23. | 9 OR 22 | 1 967 584 |
24. | “Severe Acute Respiratory Syndrome Coronavirus 2”[Supplementary Concept] | 353 |
25. | severe acute respiratory syndrome coronavirus 2[Title/abstract] | 183 |
26. | 2019nCoV[Title/Abstract] | 394 |
27. | 2019-nCov[Title/Abstract] | 402 |
28. | CoVID-19[Title/Abstract] | 1 758 |
29. | CoVID19[Title/Abstract] | 1 749 |
30. | SARS-CoV-2[Title/Abstract] | 614 |
31. | CoVid[Title/Abstract] | 1 772 |
32. | nCov[Title/Abstract] | 419 |
33. | novel coronavirus[Title/Abstract] | 1 143 |
34. | new coronavirus[Title/Abstract] | 163 |
35. | coronavirus 2019[Title/Abstract] | 228 |
36. | SARS coronavirus 2[Title/Abstract] | 5 |
37. | 24-36 (OR) | 2 850 |
38. | “Severe Acute Respiratory Syndrome”[Mesh] | 4 484 |
39. | “SARS Virus”[Mesh] | 2 916 |
40. | Severe acute respiratory syndrome[Title/Abstract] | 4 807 |
41. | SARS[Title/Abstract] | 9 046 |
42. | SARS-CoV[Title/Abstract] | 2 915 |
43. | 38-42 (OR) | 10 581 |
44. | “Coronavirus Infections”[Mesh:NoExp] | 4 679 |
45. | “Middle East Respiratory Syndrome Coronavirus”[Mesh] | 982 |
46. | MERS[Title/Abstract] | 4 156 |
47. | MERS-CoV[Title/Abstract] | 1 563 |
48. | Middle East respiratory syndrome[Title/Abstract] | 1 818 |
49. | Middle East respiratory syndrome-related coronavirus[Title/Abstract] | 10 |
50. | EMC/2012 | 15 |
51. | 44-50 (OR) | 7 923 |
52. | 37 OR 43 OR 51 | 18 852 |
53. | 23 OR 52 | 1 977 403 |
Intervention: | ||
54. | Clinical frailty scale[Title/Abstract] | 295 |
55. | Csha-cfs[Title/Abstract] | 19 |
56. | frailty index[Title/Abstract] | 1 238 |
57. | 54 OR 55 OR 56 | 1 489 |
Combined sets: | ||
58. | 23 AND 57 | 183 |
59. | 53 AND 57 | 183 |
Limits: | ||
60. | 59 and limit 2017 - | 133 |
Final 60 | 133 |
/de = Term from the EMTREE controlled vocabulary; /exp = Includes terms found below this term in the EMTREE hierarchy; /mj = Major Topic; :ab = Abstract; :au = Author; :ti = Article Title; :ti,ab = Title or abstract; * = Truncation; ’ ’ = Citation Marks; searches for an exact phrase | ||
Search terms | Items found | |
Population: | ||
1. | ‘intensive care’/exp | 699 967 |
2. | ‘intensive care unit’/exp | 186 548 |
3. | ‘critical illness’/exp | 28 616 |
4. | ‘critically ill patient’/exp | 42 781 |
5. | ‘critical care’:ti,ab,kw | 45 100 |
6. | ‘critical illness’:ti,ab,kw | 11 979 |
7. | ‘critically ill’:ti,ab,kw | 63 867 |
8. | ‘intensive care’:ti,ab,kw | 202 584 |
9. | ‘icu’:ti,ab,kw | 111 350 |
10. | 1-9 (OR) | 916 778 |
11. | ‘assisted ventilation’/exp | 168 620 |
12. | ‘respiratory failure’/exp | 101 148 |
13. | ‘virus pneumonia’/exp | 15 552 |
14. | ‘viral respiratory tract infection’/exp | 3 886 |
15. | ‘ventilat*’:ti,ab,kw | 239 525 |
16. | ‘respirat*’:ti,ab,kw | 651 176 |
17. | ‘airway*’:ti,ab,kw | 229 402 |
18. | ‘intubat*’:ti,ab,kw | 86 825 |
19. | ‘influenza’:ti,ab,kw | 111 342 |
20. | ‘pneumoni*’ :ti,ab,kw | 249 310 |
21. | ‘pulmonary’:ti,ab,kw | 730 432 |
22. | ‘lung*’:ti,ab,kw | 932 588 |
23. | 11-22 (OR) | 2 435 961 |
24. | 10 OR 23 | 3 035 795 |
25. | ‘coronavirus disease 2019’/exp | 166 |
26. | ‘sars-related coronavirus’/de | 46 |
27. | ‘severe acute respiratory syndrome coronavirus 2’:ti,ab,kw | 113 |
28. | ‘2019-ncov’:ti,ab,kw | 344 |
29. | ‘covid-19’:ti,ab,kw | 1 104 |
30. | ‘covid19’:ti,ab,kw | 9 |
31. | ‘sars-cov-2':ti,ab,kw | 401 |
32. | ‘covid’:ti,ab,kw | 1 117 |
33. | ‘ncov’:ti,ab,kw | 359 |
34. | ‘novel coronavirus’:ti,ab,kw | 1 016 |
35. | ‘new coronavirus’:ti,ab,kw | 151 |
36. | ‘coronavirus 2019’:ti,ab,kw | 194 |
37. | ‘sars coronavirus 2’:ti,ab,kw | 7 |
38. | 25-37 (OR) | 2 199 |
39. | ‘severe acute respiratory syndrome’/exp | 8 242 |
40. | ‘sars coronavirus’/exp | 4 858 |
41. | ‘severe acute respiratory syndrome’:ti,ab,kw | 4 956 |
42. | ‘sars’:ti,ab,kw | 9 674 |
43. | ‘sars-cov’:ti,ab,kw | 2 804 |
44. | 39-43 (OR) | 14 056 |
45. | ‘middle east respiratory syndrome coronavirus’/exp | 1 886 |
46. | ‘middle east respiratory syndrome’/exp | 1 031 |
47. | ‘mers’:ti,ab | 4 456 |
48. | ‘mers-cov’:ti,ab | 1 659 |
49. | ‘middle east respiratory syndrome’:ti,ab | 1 905 |
50. | ‘emc/2012’:ti,ab | 24 |
51. | 45-50 (OR) | 5 253 |
52. | 38 OR 44 OR 51 | 19 516 |
53. | 24 OR 52 | 3 044 399 |
Intervention: | ||
54. | ‘clinical frailty scale’/exp | 128 |
55. | ‘frailty index’/exp | 185 |
56. | ‘clinical frailty scale’:ab,ti,kw | 604 |
57. | ‘csha-cfs’:ab,ti,kw | 34 |
58. | ‘frailty index’:ab,ti,kw | 2 001 |
59. | 54-58 (OR) | 2 592 |
Combined sets | ||
60. | 24 AND 59 | 428 |
61. | 53 AND 59 | 428 |
Limits: | ||
62. | 61 limit 2017 - | 284 |
Final | 284 |
The search result, usually found at the end of the documentation, forms the list of abstracts.; TITLE-ABS-KEY = Title or abstract or keywords; * = Truncation | ||
Search terms | Items found | |
Population: | ||
1. | TITLE-ABS-KEY(“critical care”) | 70 360 |
2. | TITLE-ABS-KEY(“critical illness”) | 44 195 |
3. | TITLE-ABS-KEY(“critically ill”) | 59 453 |
4. | TITLE-ABS-KEY(“intensive care”) | 289 685 |
5. | TITLE-ABS-KEY(ICU) | 66 375 |
6. | 1-5 (OR) | 349 952 |
7. | TITLE-ABS-KEY(ventilat*) | 347 495 |
8. | TITLE-ABS-KEY(respirat*) | 1 097 689 |
9. | TITLE-ABS-KEY(airway) | 228 056 |
10. | TITLE-ABS-KEY(intubat*) | 115 733 |
11. | TITLE-ABS-KEY(influenza) | 151 754 |
12. | TITLE-ABS-KEY(pneumoni*) | 370 746 |
13. | TITLE-ABS-KEY(pulmonary) | 775 658 |
14. | TITLE-ABS-KEY(lung) | 1 471 367 |
15. | 7-14 (OR) | 2 938 457 |
16. | 6 OR 15 | 3 152 556 |
17. | TITLE-ABS-KEY ( "severe acute respiratory syndrome coronavirus 2" ) | 308 |
18. | TITLE-ABS-KEY ( "2019-ncov" ) | 259 |
19. | TITLE-ABS-KEY ( "covid-19" ) | 796 |
20. | TITLE-ABS-KEY ( "covid19" b) | 3 |
21. | TITLE-ABS-KEY ( "sars-cov-2" ) | 248 |
22. | TITLE-ABS-KEY ( "covid" ) | 804 |
23. | TITLE-ABS-KEY ( "ncov" ) | 276 |
24. | TITLE-ABS-KEY ( "novel coronavirus" ) | 871 |
25. | TITLE-ABS-KEY ( "new coronavirus" ) | 152 |
26. | TITLE-ABS-KEY ( "coronavirus 2019" ) | 151 |
27. | TITLE-ABS-KEY ( "sars coronavirus 2" ) | 14 |
28. | 17-27 (OR) | 1 634 |
29. | TITLE-ABS-KEY ( "severe acute respiratory syndrome" ) | 10 545 |
30. | TITLE-ABS-KEY ( "sars" ) | 100 532 |
31. | TITLE-ABS-KEY ( "sars-cov" ) | 2 765 |
32. | 29-31 (OR) | 103 904 |
33. | TITLE-ABS-KEY ( "mers" ) | 32 349 |
34. | TITLE-ABS-KEY ( "mers-cov" ) | 1 587 |
35. | TITLE-ABS-KEY ( "middle east respiratory syndrome" ) | 2 576 |
36. | TITLE-ABS-KEY( "emc/2012" ) | 41 |
37. | 33-36 (OR) | 33 120 |
38. | 28 OR 32 OR 37 | 136 593 |
39. | 16 OR 38 | 3 272 784 |
Intervention: | ||
40. | TITLE-ABS-KEY(“clinical frailty scale”) | 330 |
41. | TITLE-ABS-KEY(csha-cfs) | 21 |
42. | TITLE-ABS-KEY(“frailty index”) | 1 356 |
43. | 40-42 (OR) | 1 635 |
Combined sets: | ||
44. | 16 AND 43 | 280 |
45. | 39 AND 43 | 280 |
Limits: | ||
46. | 45 limit 2017 - | 203 |
Final | 203 |
The search result, usually found at the end of the documentation, forms the list of abstracts.; AB = Abstract; DE = Term from the thesaurus; MM = Major Concept; TI = Title; * = Truncation; “ “ = Citation Marks; searches for an exact phrase | ||
Search terms | Items found | |
Population: | ||
1. | MH “Critical Care” | 23 830 |
2. | MH “Critical Illness” | 12 216 |
3. | MH “Critically Ill Patients” | 13 452 |
4. | MH “Intensive Care Units” | 40 072 |
5. | MH “Respiratory Care Units” | 181 |
6. | TI "critical care" OR AB "critical care" | 23 198 |
7. | TI "Critical illness" OR AB "Critical illness" | 4 474 |
8. | TI "critically ill" OR AB "critically ill" | 21 775 |
9. | TI "Intensive care" OR AB "Intensive care" | 64 499 |
10. | TI "ICU" OR AB "ICU" | 28 650 |
11. | 1-10 (OR) | 126 925 |
12. | MH “Respiration, Artificial+” | 33 869 |
13. | MH “Respiratory Failure+” | 14 861 |
14. | MH “Airway Management+” | 21 225 |
15. | MH “Ventilator Patients” | 2 659 |
16. | MH “Pneumonia, Viral” | 728 |
17. | MH “Influenza, Human” | 5 978 |
18. | TI "ventila*" OR AB "ventilat*" | 49 016 |
19. | TI "respirat*" OR AB "respirat*" | 89 112 |
20. | TI "airway*" OR AB "airway*" | 34 603 |
21. | TI "intubat*" OR AB "intubat*" | 17 001 |
22. | TI "influenza" OR AB "influenza" | 19 137 |
23. | TI "pneumoni*" OR AB "pneumoni*" | 34 343 |
24. | TI "pulmonary" OR AB "pulmonary" | 95 961 |
25. | TI "lung*" OR AB "lung*" | 108 749 |
26. | 12-25 (OR) | 353 075 |
27. | 11 OR 26 | 445 634 |
28. | TI "severe acute respiratory syndrome coronavirus 2" OR AB "severe acute respiratory syndrome coronavirus 2” | 14 |
29. | TI "2019 nCoV" OR AB "2019 nCoV” | 2 |
30. | TI “2019-nCov” OR AB “2019-nCov” | 75 |
31. | TI CoVID-19 OR AB CoVID-19 | 233 |
32. | TI CoVID19 OR AB CoVID19 | 2 |
33. | TI SARS-CoV-2 OR AB SARS-CoV-2 | 43 |
34. | TI “SARS CoV 2” OR AB “SARS CoV 2” | 1 |
35. | TI CoVid OR AB CoVid | 3 |
36. | TI nCov OR AB nCov | 9 |
37. | TI “novel coronavirus” OR AB “novel coronavirus” | 231 |
38. | TI “new coronavirus” OR AB “new coronavirus” | 39 |
39. | TI "coronavirus 2019” OR AB coronavirus 2019” | 90 |
40. | 28-39 (OR) | 479 |
41. | MH “Severe Acute Respiratory Syndrome” | 1 997 |
42. | MH “SARS Virus” | 158 |
43. | TI “Severe acute respiratory syndrome” OR AB “Severe acute respiratory syndrome” | 1 056 |
44. | TI SARS OR AB SARS | 2 304 |
45. | TI SARS-CoV OR AB SARS-CoV | 99 |
46. | 41-45 (OR) | 3 332 |
47. | MH “Middle East Respiratory Syndrome Coronavirus” | 372 |
48. | MH “Middle East Respiratory Syndrome” | 245 |
49. | TI MERS OR AB MERS | 959 |
50. | TI MERS-CoV OR AB MERS-CoV | 400 |
51. | TI “Middle East respiratory syndrome” OR AB “Middle East respiratory syndrome” | 611 |
52. | TI “Middle East respiratory syndrome-related coronavirus” OR AB “Middle East respiratory syndrome-related coronavirus” | 2 |
53. | TI “EMC/2012” OR AB “EMC/2012” | 4 |
54. | 47-53 (OR) | 1 195 |
55. | 40 OR 46 OR 54 | 4 711 |
56. | 27 OR 55 | 446 435 |
Intervention: | ||
57. | TI “clinical frailty scale” OR AB “clinical frailty scale” | 202 |
58. | TI “csha-cfs” OR AB “csha-cfs” | 14 |
59. | TI “frailty index” OR AB “frailty index” | 728 |
60. | 57-59 (OR) | 903 |
Combined sets: | ||
61. | 27 AND 60 | 105 |
62. | 56 AND 60 | 105 |
Limits: | ||
63. | 62 limit 2017 - | 67 |
Final | 67 |